Company intelligence / Profile preview
Innoviva Specialty Therapeutics
Waltham, Massachusetts, United States
- Ownership
- Private
- Employees
- ~121
- Development stage
- Other
01
Overview
Innoviva Specialty Therapeutics commercializes four FDA-approved products in critical care and infectious disease (GIAPREZA, XERAVA, XACDURO, ZEVTERA) and leads a late-stage, pivotal program (zoliflodacin, completed Phase 3) for uncomplicated gonorrhea. Multiple programs target antimicrobial-resistant pathogens, including those with limited current treatment options.
- Therapeutic areas
- Infectious DiseasesCardiovascular
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GlaxoSmithKline (GSK)Global Antibiotic Research & Development Partnership (GARDP)
Beyond the preview
Go deeper on Innoviva Specialty Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innoviva Specialty Therapeutics.